Integril 0.75

Introduction
Integril 0.75 is a blood thinner which prevents formation of harmful blood clots. It is used in the treatment of a heart attack and also prevents the clotting of blood in the heart during an angioplasty (procedure to improve blood flow to the heart). Integril 0.75 is administered under the supervision of a doctor. Your doctor will decide the dose and duration of the medicine for you. You should continue all your other medicines that are advised by the doctor for your long-term treatment even after this injection. Use of this medicine may cause low blood platelets and increase your risk of bleeding. Let your doctor know immediately if you see pinpoint rash or blood in your vomits, urine, or stool. It may also cause low blood pressure as a side effect. Your doctor will explain the benefits and risks associated with this medicine before it is administered. This medicine is used with caution for some people. Before taking it, you must inform the doctor if you are suffering from any bleeding disorder, kidney or liver disease. Also, let your doctor know if you are pregnant or breastfeeding and about all the other medications that you are taking regularly.

_
Uses of Integril 0.75
Heart attack
Side effects of Integril 0.75
Common
Bleeding
Decreased blood pressure
How to use Integril 0.75
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Integril 0.75 works
Integril 0.75 is an antiplatelet medication. It works by preventing the platelets from sticking together, thereby decreasing the formation of harmful blood clots.
What if you forget to take Integril 0.75?
If you miss a dose of Integril 0.75, please consult your doctor.
Quick Tips
It is usually given by your nurse or doctor as an infusion (drip) into a vein.
It increases your risk of bleeding. Be careful while shaving, cutting fingernails or toenails or using sharp objects.
Notify your doctor if you see blood in your vomit, urine or stool (black, tarry stools or bright red blood).
Brief Description
Indication
Myocardial infarction, Unstable angina, Angioplasty, Percutaneous coronary intervention (PCI)
Adult Dose
Intravenous Unstable angina Adult: 180 mcg/kg via IV inj followed by 2 mcg/kg per minute by IV infusion for up to 72 hr. If percutaneous coronary intervention (PCI) is performed during therapy, infusion should be continued for 18-24 hr after procedure, up to a maximum total duration of 96 hr of therapy. Angioplasty Adult: Initially, 180 mcg/kg via IV inj, to be given immediately before procedure, followed by 2 mcg/kg/minute via IV infusion. A second dose of 180 mcg/kg via IV inj should be given 10 minutes after the 1st dose. Continue infusion until hospital discharge or for up to 18-24 hr (minimum treatment duration: 12 hr).

_
Renal Dose
Renal Impairment (CrCl <50 mL/min) ACS: 180 mcg/kg IV, THEN continuous infusion 1 mcg/kg/min PCI: 180 mcg/kg IV, THEN continuous infusion 1 mcg/kg/min with another 180 mcg/kg IV bolus 10 minutes after 1st one Hemodialysis: Safety and using during hemodialysis not established _ Contraindication Active bleeding, increased risk of haemorrhage including hemorrhagic disorders, cerebrovascular disorders, history of stroke, uncontrolled hypertension, severe trauma, severe renal impairment, recent major surgery. Lactation. Mode of Action Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor thus preventing platelet aggregation and thrombosis. Precaution Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic therapy is required. Hepatic impairment, platelet counts <100,000 mm3; hemorrhagic retinopathy, drugs affecting haemostasis. Check APTT or ACT prior to sheath removal. Severe renal impairment, vasculitis, haemorrhagic retinopathy, acute pericarditis or aortic dissection. Pregnancy. Lactation: excretion in milk unknown; use with caution _ Side Effect 1-10% Bleeding (8%),Hypotension (7%),Thrombocytopenia (2.3%),Injection site reaction <1% Hypersensitivity,Intracranial hemorrhage,Pulmonary hemorrhage,Thrombocytopenia,GI hemorrhage _ Pregnancy Category Note Pregnancy Category: B Lactation: excretion in milk unknown; use with caution _ Interaction Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents. _